Key result
TAVI improves symptoms and quality of life in severe AS, though frailty predicts worse outcomes.
Why the study?
There is little data on the quality of life of patients undergoing TAVI and the factors that influence it, with no specific tool to assess the impact of AS and guide treatment strategy.
Answers are grounded in this paper and cite their sources.
This review highlights the lack of specific tools to assess the impact of severe aortic stenosis and the need for more data on quality of life following TAVI to guide appropriate treatment strategies.
Severe aortic stenosis (AS) is the most common valvular heart disease, with an increasing prevalence due to age-related degenerative modifications of the valve. Once AS becomes symptomatic, the survival of patients is significantly reduced with an annual mortality rate of 25%. Depending on surgical risk, anatomical and technical aspects, and the patient’s option, correction can be made either by surgical valve replacement (SAVR) or by transcatheter aortic valve implantation (TAVI). Although aortic valve implantation brings relief of symptoms, there is little data on the quality of life (QoL) of patients undergoing TAVI and the factors that directly influence it. Even if age and comorbidities are known modifiers of survival, there is no specific tool to assess the impact of AS and to determine the appropriate treatment strategy.
No takes yet. Share an insight, caveat, or question.
Radulescu et al. (2021) conducted a review in Severe aortic stenosis. Transcatheter aortic valve implantation (TAVI) vs. Surgical aortic valve replacement (SAVR) or standard therapy was evaluated. Transcatheter aortic valve implantation provides symptom relief and improves quality of life in severe aortic stenosis, though frailty independently predicts deterioration in quality of life.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: